Ruth Ottman

Ruth Ottman

Auto-generated profile, based on publicly available information

Ruth Ottman

Columbia University 1 Department of Epidemiology, Mailman School of Public Health New York, New York

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2009 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
Ellen SidranskyEllen Sidransky
Ellen Sidransky
MNM.A. Nalls
M.A. Nalls
JAJ.O. Aasly
J.O. Aasly
JAJ. Aharon-Peretz
J. Aharon-Peretz
GAG. Annesi
G. Annesi
SZS.G. Ziegler
S.G. Ziegler
Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel–Haenszel procedure used to estimate odds ratios across centers. All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non–Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non–Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.

27 January 1999 in JAMA
Verified
Journal Article
Closed access
CTCaroline M. Tanner
Caroline M. Tanner
RORuth Ottman
Ruth Ottman
SGSamuel M. Goldman
Samuel M. Goldman
JEJonas Ellenberg
Jonas Ellenberg
PCPiu Chan
Piu Chan
JLJ. William Langston
J. William Langston
The cause of Parkinson disease (PD) is unknown. Genetic linkages have been identified in families with PD, but whether most PD is inherited has not been determined. To assess genetic inheritance of PD by studying monozygotic (MZ) and dizygotic (DZ) twin pairs. Twin study comparing concordance rates of PD in MZ and DZ twin pairs. A total of 19842 white male twins enrolled in the National Academy of Sciences/National Research Council World War II Veteran Twins Registry were screened for PD and standard diagnostic criteria for PD were applied. Zygosity was determined by polymerase chain reaction or questionnaire. Parkinson disease concordance in twin pairs, stratified by zygosity and age at diagnosis. Of 268 twins with suspected parkinsonism and 250 presumed unaffected twin brothers, 193 twins with PD were identified (concordance-adjusted prevalence, 8.67/1000). In 71 MZ and 90 DZ pairs with complete diagnoses, pairwise concordance was similar (0.129 overall, 0.155 MZ, 0.111 DZ; relative risk, 1.39; 95% confidence interval, 0.63-3.1). In 16 pairs with diagnosis at or before age 50 years in at least 1 twin, MZ concordance was 1.0 (4 pairs), and DZ was 0.167 (relative risk, 6.0; 95% confidence interval, 1.69-21.26). The similarity in concordance overall indicates that genetic factors do not play a major role in causing typical PD. No genetic component is evident when the disease begins after age 50 years. However, genetic factors appear to be important when disease begins at or before age 50 years.

28 January 2002 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SKSergey Kalachikov
Sergey Kalachikov
OEOleg Evgrafov
Oleg Evgrafov
BRBarbara Ross
Barbara Ross
MWMelodie Winawer
Melodie Winawer
CBChristie Barker-Cummings
Christie Barker-Cummings
TGT. Conrad Gilliam
T. Conrad Gilliam

1 March 1995 in Neurology
Verified
Journal Article
Closed access
PDF file
RMR. Mayeux
R. Mayeux
ROR. Ottman
R. Ottman
GMG. Maestre
G. Maestre
CNC. Ngai
C. Ngai
MTM.-X. Tang
M.-X. Tang
MSM. Shelanski
M. Shelanski
Article abstract-The apolipoprotein-epsilon4 allele increases the risk of Alzheimer9s disease (AD), but cerebral deposition of beta-amyloid with age, a genetic mutation, or head injury may contribute to the pathogenesis of this disease. We examined the risks of AD associated with traumatic head injury and apolipoprotein-epsilon4 in 236 community-dwelling elderly persons. A 10-fold increase in the risk of AD was associated with both apolipoprotein-epsilon4 and a history of traumatic head injury, compared with a two-fold increase in risk with apolipoprotein-epsilon4 alone. Head injury in the absence of an apolipoprotein-epsilon4 allele did not increase risk. These data imply that the biological effects of head injury may increase the risk of AD, but only through a synergistic relationship with apolipoprotein-epsilon4. NEUROLOGY 1995;45: 555-557

1 October 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SASilke Appenzeller
Silke Appenzeller
RBRudi Balling
Rudi Balling
NBNina Barisic
Nina Barisic
SBStéphanie Baulac
Stéphanie Baulac
HCHande Caglayan
Hande Caglayan
ERElizabeth K. Ruzzo
Elizabeth K. Ruzzo

1 January 1998 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
ELElan D. Louis
Elan D. Louis
RORuth Ottman
Ruth Ottman
WHW. Allen Hauser
W. Allen Hauser